Aedas Homes, S.A. (0RV8)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 22.48 |
|---|---|
| 52-week range | 21.10 – 24.05 |
| Return, 1 month / 3 months | −2.6% / +2.0% |
| Return, 1 year / 3 years | +5.8% / +110.4% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 15.5% |
| Worst drawdown (1 year) | -11.9% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Aedas Homes is a Spanish homebuilder based in Madrid that develops and sells new residential properties across Spain. It focuses on apartments and houses for private buyers, working in major cities and coastal areas where demand for new housing is strong. The company manages land acquisition, design and construction, and then markets the finished homes directly to individual purchasers. Its customers are mainly people looking to own a newly built home, whether as a main residence or a second property.
The shares are listed on the London Exchange in UK under the code 0RV8, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Aedas Homes, S.A. (0RV8) trades on the London Exchange in UK. It last closed at EUR 22.48 on 21 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,741 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.8% and over the last three months it rose 2.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -2.2% | ||
| From 52-week high | -6.5% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.0% | ||
| 6-month return | -2.4% | ||
| 12-month return, skipping the last month | 8.6% | ||
| Stability (higher is calmer) | 93 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 15.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -11.9% | ||
| Liquidity | 2 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 33.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.3% |
|---|---|
| 1 month | −2.6% |
| 3 months | +2.0% |
| 6 months | −2.4% |
| 1 year | +5.8% |
| 3 years | +110.4% |
| 5 years | +69.2% |
Signals
| 50-day / 200-day average | 22.28 / 22.98 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jul 2025 | EUR 3.1500 |
| 19 Dec 2024 | EUR 0.9000 |
| 30 Jul 2024 | EUR 1.3500 |
| 22 Mar 2024 | EUR 2.2500 |
| 27 Jul 2023 | EUR 1.1500 |
| 29 Mar 2023 | EUR 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.